Astellas Pharma $3 billion acquisition of Audentes Therapeutics

Overview:

• Tokyo based pharmaceutical company Astellas Pharma announced plans to acquire San Francisco based genetics medicine company Audentes Therapeutics for $3 billion.
• Astellas will pay $60 per share to acquire Audentes, a 110% premium from Audentes’ December 2, 2019 closing price of $28.61.
• Morgan Stanley, through Mitsubishi UFJ Morgan Stanley Securities, is the exclusive financial adviser to Astellas. Centerview Partners is the exclusive financial adviser to Audentes.
• Upon its projected date of Q1 2020, this acquisition will be the second largest for Astellas.

Chynna Lewis – Researcher